THC in Rome's Hashish Nearly Doubled in 7 Years — From 13.7% to 27.1%

Observational analysis of over 1,000 hashish (cannabis resin) samples seized by law enforcement in the southern Rome area from 2015 to 2022. THC concentration was measured for each sample. Data analyzed for trends over time and by demographic characteristics of individuals involved in seizures.

Potency matters because dose determines risk. A joint of 27% THC hashish delivers nearly twice the THC of the same amount of 14% hashish. If health risks — psychosis, dependence, cognitive effects — are dose-dependent (and evidence increasingly says they are), then the same amount of cannabis use in 2022 carries roughly twice the risk it did in 2015. This European data point is critical because it shows potency escalation is a global trend, not a quirk of the U.S. or Canadian legal markets.

This is the European companion to the potency trilogy already in the database. RTHC-00071 tracked rising THC in U.S. products, RTHC-00049 documented European potency trends, and RTHC-00086 showed that dispensary THC:CBD ratios overshoot therapeutic targets. This Rome data adds a time-series from the illicit market showing the same pattern. The potency escalation is happening everywhere — legal, illegal, North America, Europe — and it's accelerating.

Law enforcement seizures are not a random sample of all cannabis in circulation — they may overrepresent larger quantities or specific trafficking routes. The study only analyzed hashish (resin), not herbal cannabis (marijuana), which may have different potency trends. No data on what consumers actually smoke per session (higher potency could lead to titration — using less per session). Southern Rome may not represent all Italian or European markets. No direct health outcome data — the link between rising potency and health effects is inferred from other research.